Julia K. Rotow, MD

home / authors / julia-k.-rotow,-md

Articles

Joshua K. Sabari, MD;Christine Bestvina, MD ;Mark Kris, MD;Julia K. Rotow, MD

March 12th 2025

Panelists discuss next-generation ROS1 inhibition, highlighting emerging therapies, their mechanisms of action, and potential benefits for patients with ROS1-positive metastatic non–small cell lung cancer.

Case 2—Metastatic NSCLC With a ROS1 Alteration: Presentation and Discussion

Joshua K. Sabari, MD;Christine Bestvina, MD ;Mark Kris, MD;Julia K. Rotow, MD

March 12th 2025

Panelists discuss the presentation and management of a case involving metastatic non–-small cell lung cancer (NSCLC) with a ROS1 alteration, focusing on treatment approaches and clinical considerations

KRAS Inhibition: On the Horizon

Joshua K. Sabari, MD;Christine Bestvina, MD ;Mark Kris, MD;Julia K. Rotow, MD

March 5th 2025

Panelists discuss the emerging potential of KRAS inhibition in metastatic cancer treatment, exploring novel therapies and their promise for patients with KRAS-mutated tumors.

KRAS-Mutated Metastatic NSCLC: Individualized Treatment Selection

Joshua K. Sabari, MD;Christine Bestvina, MD ;Mark Kris, MD;Julia K. Rotow, MD

March 5th 2025

Panelists discuss individualized treatment selection for KRAS-mutated metastatic non–-small cell lung cancer (NSCLC), focusing on targeted therapies and personalized approaches to improve patient outcomes.

KRAS Inhibitors for NSCLC: Efficacy and Safety

Joshua K. Sabari, MD;Christine Bestvina, MD ;Mark Kris, MD;Julia K. Rotow, MD

February 26th 2025

Panelists discuss the efficacy and safety of KRAS inhibitors for non–-small cell lung cancer (NSCLC), evaluating clinical trial results and their potential impact on treatment strategies.

Case Presentation: Second-Line Decision- Making for KRAS-Mutated Metastatic NSCLC

Joshua K. Sabari, MD;Christine Bestvina, MD ;Mark Kris, MD;Julia K. Rotow, MD

February 26th 2025

Panelists discuss second-line treatment decision-making for KRAS-mutated metastatic non–-small cell lung cancer (NSCLC), focusing on available therapies and personalized approaches based on patient characteristics.

Case 1 Presentation—KRAS-Mutated Metastatic NSCLC: First-Line Decision- Making

Joshua K. Sabari, MD;Christine Bestvina, MD ;Mark Kris, MD;Julia K. Rotow, MD

February 19th 2025

Panelists discuss first-line treatment decision-making for KRAS-mutated metastatic non–-small cell lung cancer (NSCLC), focusing on the selection of targeted therapies and factors influencing clinical choices.

Use of RNA-Based Molecular Panels in Metastatic NSCLC

Joshua K. Sabari, MD;Christine Bestvina, MD ;Mark Kris, MD;Julia K. Rotow, MD

February 19th 2025

Panelists discuss the use of RNA-based molecular panels in metastatic non–-small cell lung cancer (NSCLC), highlighting their role in guiding personalized treatment decisions and improving patient outcomes.

Metastatic NSCLC: Decision-Making When Molecular Testing Results Are Delayed

Joshua K. Sabari, MD;Christine Bestvina, MD ;Mark Kris, MD;Julia K. Rotow, MD

February 12th 2025

Panelists discuss decision-making in metastatic non–-small cell lung cancer (NSCLC) when molecular testing results are delayed, focusing on strategies to optimize treatment while awaiting results.

Molecular Testing for Metastatic NSCLC

Joshua K. Sabari, MD;Christine Bestvina, MD ;Mark Kris, MD;Julia K. Rotow, MD

February 12th 2025

Panelists discuss the role of molecular testing in metastatic non–-small cell lung cancer (NSCLC), emphasizing its importance in identifying actionable mutations and guiding personalized treatment strategies.